Aquestive Therapeutics, Inc.

NASDAQ:AQST

Drug Manufacturers - Specialty & Generic

Healthcare
$3.78 +5.08%

+$0.23 today

Market cap
$475.10M
Beta
1.45
P/E (TTM)
-8.3
EPS (TTM)
-$0.56
52W Low $2.93High $7.55

Volume 1.80M

Average 1.51M

AQST Pre-Tax Margin

Income before tax as a percentage of revenue.

Aquestive Therapeutics, Inc.NASDAQ: AQST

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -55.8%

Pre-tax margin was -55.8% in Q1 FY2026, up 207.2 pp from a year earlier. On a trailing-twelve-month basis it was -137.1%, down 37.0 pp year over year. Over 3 fiscal years it narrowed by 74.0 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-55.8%+189.0 pp QoQ
Last fiscal yearDec 2025
-188.1%-111.4 pp YoY
LTMMar 2026
-137.1%-37.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+207.2 pp——
1 year-111.4 pp——
3 years-74.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-188.1%
Year-over-year change
-111.4pp

Pre-Tax Margin vs competitors

How AQST compares with its peers on the latest reported figures

  • AQST's LTM Mar 2026 pre-tax margin of -137.1% is the lowest of the 10 companies compared; the peer median is 0.6%.
  • Its year-over-year change of -37.0 pp is the 9th highest of 10, against a peer median of -9.1 pp.
  • Over three fiscal years its change of -74.0 pp compares with a peer median of +18.1 pp.
AQST Competitors Peer median
Pre-Tax Margin for AQST and competitors
Company Period LTM level YoY 3-year change
ZVRAZevra Therapeutics, Inc.LTM Mar 2026109.1% +294.8 pp+345.2 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202614.3% -9.5 pp-5.8 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202613.6% +3.8 pp+18.1 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 20263.8% +25.2 pp+87.3 pp
ALKSAlkermes plcLTM Sep 20260.6% -25.7 pp+22.5 pp
DERMJourney Medical CorporationLTM Mar 2026-14.7% -0.1 pp+21.7 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-14.9% -27.2 pp-15.9 pp
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-17.2% -9.1 pp+6.9 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-68.7% -41.1 pp-68.6 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-137.1% -37.0 pp-74.0 pp
Peer median (excluding AQST) 0.6%-9.1 pp+18.1 pp

Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue50.83M47.68M50.58M57.56M44.55M
Cost of Revenue14.99M19.39M20.83M17.87M17.15M
Gross Profit35.84M28.29M29.75M39.69M27.39M
Gross Margin70.5%59.3%58.8%69.0%61.5%
Research & Development17.05M17.48M13.1M20.28M17.19M
Selling, General & Admin53.48M52.88M31.75M50.18M79.85M
Operating Expenses70.52M70.36M44.85M70.46M97.04M
Depreciation & Amortization2.96M2.39M1.35M718K559K
EBITDA(45.11M)(39.58M)1.18M(26.62M)(66.13M)
EBITDA Margin-88.8%-83.0%2.3%-46.2%-148.4%
Operating Income(34.68M)(42.07M)(15.1M)(30.77M)(69.65M)
Operating Margin-68.2%-88.2%-29.9%-53.5%-156.4%
Interest Income423K99K16.32M3.44M0
Interest Expense22.46M12.44M7.46M16.82M17.1M
Other Income / Expenses(35.86M)(12.34M)7.48M(13.38M)(14.13M)
Income Before Tax(70.54M)(54.41M)(7.63M)(44.15M)(83.78M)
Pre-Tax Margin-138.8%-114.1%-15.1%-76.7%-188.1%
Income Tax Expense00245K(14K)0
Net Income(70.54M)(54.41M)(7.87M)(44.14M)(83.78M)
Net Margin-138.8%-114.1%-15.6%-76.7%-188.1%
EPS (Basic)(1.85)(1.12)(0.13)(0.51)(0.76)
EPS (Diluted)(1.85)(1.12)(0.13)(0.51)(0.76)
Weighted Avg Shares38.08M48.73M61.26M86.73M121.97M
Weighted Avg Shares (Diluted)38.08M48.73M61.26M86.73M121.97M

Aquestive Therapeutics, Inc.

NASDAQ:AQST

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.